Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. (Q51371500)

4 April 2018

title

Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. (English)

1 reference

4 April 2018

1 reference

1 reference

4

1 reference

4 April 2018

author name string

Divya Samineni

series ordinal

1

1 reference

4 April 2018

Pankaj B Desai

series ordinal

2

1 reference

4 April 2018

Larry Sallans

series ordinal

3

1 reference

4 April 2018

publication date

28 June 2011

1 reference

4 April 2018

The Journal of Clinical Pharmacology

published in

1 reference

4 April 2018

volume

52

1 reference

4 April 2018

page(s)

922-931

1 reference

4 April 2018

issue

6

1 reference

4 April 2018

The Place of protease inhibitors in antiretroviral treatment

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Principles and practice of HIV-protease inhibitor pharmacoenhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Drug/Drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Gemfibrozil greatly increases plasma concentrations of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

The effect of fluconazole on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Role of the breast cancer resistance protein (ABCG2) in drug transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Expression and function of efflux drug transporters in the intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270011407494

21 January 2018

Identifiers

DOI

10.1177/0091270011407494

1 reference

4 April 2018

PubMed ID

21712498

1 reference

4 April 2018